Net Sales Report. Within thirty (30) days after the end of each Calendar Quarter, GSK shall submit to Theravance a written report setting forth Net Sales in the Territory on a Country-by-Country and Alliance Product-by-Alliance Product basis during such Calendar Quarter, total royalty payments due Theravance, relevant market share data and any payments made to any Third Party pursuant to Section 6.4.1(a) (each a "Net Sales Report").
Net Sales Report. Within thirty (30) days after the end of each ---------------- Calendar Quarter, GSK shall submit to Adolor a written report setting forth Net Sales in the ROW and the United States (but only if Adolor is receiving royalty payments based on sales in the United States) on a Country-by-Country and Collaboration Product-by-Collaboration Product basis during such Calendar Quarter, total royalty payments due Adolor, relevant market share data supporting the presence of Generic Competition, if any, and any payments made to any Third Party pursuant to Section 6.6.1 (each a "Net Sales Report"). ----------------
Net Sales Report. Within sixty (60) days following the end of each calendar quarter, BI shall submit to Vitae a written report setting forth Net Sales in the Territory on a country-by-country and Product-by-Product basis during such calendar quarter and year-to-date, total royalty payments due Vitae in respect of Products and Combination Products, and information supporting the calculation of Net Sales of Products (“Net Sales Report”).
Net Sales Report. Within thirty (30) days after the end of each Calendar Quarter, Clinigen shall submit to Theravance a written report setting forth on a Country-by-Country basis Net Sales during such Calendar Quarter, total royalty payments due Theravance, relevant market share data and any payments made to any Third Party pursuant to Section 6.03(a)(i) (each a “Net Sales Report”).
Net Sales Report. For each calendar quarter for which Licensee has an obligation to make Royalty Payments, such payments shall be accompanied by a report that specifies for such calendar quarter, on a Licensed Product-by-Licensed Product basis, the following information (“Net Sales Report”):
(i) total Net Sales of such Licensed Product in the Territory;
(ii) Net Sales on a country-by-country basis for such Licensed Product;
(iii) the exchange rate used to convert Net Sales from the currency in which they are earned to United States dollars; and
(iv) the total royalties due to Arvinas, both on a country-by-country basis and in the aggregate. For clarity, if Licensee is reporting Net Sales for more than one Licensed Product, the foregoing information shall be reported on a Licensed Product-by-Licensed Product basis.
Net Sales Report. Within sixty (60) days following the end of each Calendar Quarter, BI shall submit to Zealand Pharma a written report setting forth the Net Sales in the Territory on a country-by-country and Product-by-Product basis during such Calendar Quarter and year-to-date, total royalty payments due to Zealand Pharma in respect to Products, information showing those countries where the Adjusted Net Sales were used, and information supporting the calculation of Net Sales of Products (including the amount of gross sales of Product in the Territory) (the “Net Sales Report”).
Net Sales Report. Within thirty (30) days after the end of each Calendar Quarter, GSK shall submit to Theravance a written report setting forth Net Sales in the Territory on a Country-by-Country and Collaboration Product-by-Collaboration Product basis during such Calendar Quarter, total royalty payments due Theravance, relevant market share data and any payments made to any Third Party pursuant to Section 6.4.1(a) (each a "Net Sales Report"). [*]=CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.
Net Sales Report. Licensee shall provide POZEN, within [* * *] days after the end of each Calendar Quarter, with a report setting forth units sold, units returned and Net Sales on a Licensed Product-by-Licensed Product basis (the “Initial Royalty Report”).
Net Sales Report. Serono shall use commercially reasonable efforts to deliver to OSI within forty-five (45) days, but in no event later than sixty (60) days, after the end of each Calendar Quarter during the Term a report of Net Sales during such Calendar Quarter and on a cumulative basis for the applicable Calendar Year, including (i) an accounting of the deductions from Net Sales permitted by the definition thereof, and (ii) adjustments, if any, to Net Sales permitted by the definition thereof.
Net Sales Report. ROCHE shall, within sixty (60) days after the last day of each Calendar Quarter commencing [***], deliver to CHIRON a true and accurate report for the prior Calendar Quarter, substantially in the form attached as Exhibit E to this Agreement, which shall state the amount of monies due hereunder, if any, as Earned Royalties and Minimum Royalties, and shall include all information reasonably necessary to calculate such amount, including, but not limited to, the following information, presented for the Region by product and Product Category (as defined in paragraph 2 of Exhibit A):
(a) the amount of Net Sales, expressed in United States Dollars (with applicable exchange rates to the extent specifically requested in writing by CHIRON), and the applicable Earned Royalty rate or rates, and all credits and adjustments thereto;
(b) the number of Units Shipped and the applicable Minimum Royalty Amounts, and adjustments to Units Shipped (returns, replacements, etc.); and
(c) a statement of the basis for any deviation from the Earned Royalty rates and Minimum Royalty Amounts as expressed in paragraphs 1 and 2 of Exhibit A.
